Cowen set a $9.00 price objective on Teva Pharmaceutical Industries (NYSE:TEVA) in a research report report published on Wednesday, TipRanks reports. The brokerage currently has a hold rating on the stock.
TEVA has been the subject of a number of other reports. Morgan Stanley cut shares of Teva Pharmaceutical Industries from an equal weight rating to an underweight rating and reduced their price objective for the stock from $16.00 to $6.00 in a research note on Monday, July 15th. Barclays started coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, June 11th. They issued an underweight rating and a $8.00 price objective for the company. SunTrust Banks reduced their price objective on shares of Teva Pharmaceutical Industries to $7.00 and set a hold rating for the company in a research note on Thursday. Citigroup set a $13.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a buy rating in a research note on Monday, June 17th. Finally, Royal Bank of Canada reissued a hold rating and issued a $10.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Thursday. Six investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of Hold and a consensus price target of $13.21.
TEVA stock traded down $0.27 during midday trading on Wednesday, reaching $7.02. 19,402,224 shares of the company’s stock traded hands, compared to its average volume of 22,598,402. Teva Pharmaceutical Industries has a 52-week low of $6.34 and a 52-week high of $25.96. The company has a market cap of $7.41 billion, a PE ratio of 2.51, a P/E/G ratio of 0.76 and a beta of 1.64. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The stock’s 50-day moving average is $8.40.
In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the completion of the transaction, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sol J. Barer acquired 111,000 shares of the stock in a transaction on Monday, June 3rd. The shares were acquired at an average price of $8.98 per share, with a total value of $996,780.00. Following the transaction, the director now directly owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in TEVA. Charles Schwab Investment Management Inc. increased its stake in Teva Pharmaceutical Industries by 15.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 394,805 shares of the company’s stock worth $3,645,000 after buying an additional 53,963 shares during the period. Caisse DE Depot ET Placement DU Quebec increased its stake in Teva Pharmaceutical Industries by 1.0% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 815,921 shares of the company’s stock worth $7,531,000 after buying an additional 8,235 shares during the period. Fortem Financial Group LLC purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $408,000. Skandinaviska Enskilda Banken AB publ increased its stake in Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 234,920 shares of the company’s stock worth $2,169,000 after buying an additional 18,055 shares during the period. Finally, Cutler Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 19.2% in the 2nd quarter. Cutler Capital Management LLC now owns 106,697 shares of the company’s stock worth $984,000 after buying an additional 17,169 shares during the period. Institutional investors and hedge funds own 65.69% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Inflation
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.